{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:42Z","timestamp":1786991622061,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":1834,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jchf.2012.09.001","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T16:50:15Z","timestamp":1361465415000},"page":"72-78","source":"Crossref","is-referenced-by-count":179,"title":["The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in\u00a0Advanced Renal Cell Carcinoma Patients"],"prefix":"10.1016","volume":"1","author":[{"given":"Philip S.","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Harshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2012.09.001_bib1","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1200\/JCO.2008.18.5439","article-title":"Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?","volume":"26","author":"Lenihan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2012.09.001_bib2","first-page":"CD003917","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jchf.2012.09.001_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/FJC.0b013e3181e0f89a","article-title":"Cancer therapy-associated cardiotoxicity and signaling in the myocardium","volume":"56","author":"Zuppinger","year":"2010","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.jchf.2012.09.001_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1634\/theoncologist.2011-S2-45","article-title":"Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow","volume":"16","author":"Molina","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.jchf.2012.09.001_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1592\/phco.29.4.473","article-title":"Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature","volume":"29","author":"Wong","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jchf.2012.09.001_bib6","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2012.09.001_bib7","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2012.09.001_bib8","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1200\/JCO.2010.34.4309","article-title":"Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib","volume":"29","author":"Richards","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2012.09.001_bib9","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cncr.23460","article-title":"Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor","volume":"112","author":"Khakoo","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jchf.2012.09.001_bib10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","article-title":"Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate","volume":"19","author":"Telli","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jchf.2012.09.001_bib11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jchf.2012.09.001_bib12","unstructured":"Sunitinib prescribing information. Pfizer, New York, NY. Available at: http:\/\/www.pfizer.com\/pfizer\/download\/uspi_sutent.pdf. Accessed November 3,\u00a02012."},{"key":"10.1016\/j.jchf.2012.09.001_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","article-title":"Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma","volume":"12","author":"Rock","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.jchf.2012.09.001_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2012.09.001_bib15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A\u00a0phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2012.09.001_bib16","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2012.09.001_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2012.09.001_bib18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2012.09.001_bib19","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2011.40.4012","article-title":"Underestimating cardiac toxicity in cancer trials: lessons learned?","volume":"30","author":"Witteles","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2012.09.001_bib20","unstructured":"National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 US Department of Health and Human Services, NIH. Bethesda, MD: June 14, 2010; Publication No. 09-5410."},{"key":"10.1016\/j.jchf.2012.09.001_bib21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2012.09.001_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2012.09.001_bib23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jchf.2012.09.001_bib24","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1124\/mol.108.050104","article-title":"Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib","volume":"74","author":"Hasinoff","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jchf.2012.09.001_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12012-009-9056-0","article-title":"Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib","volume":"10","author":"Hasinoff","year":"2010","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jchf.2012.09.001_bib26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jchf.2012.09.001_bib27","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0735-1097(03)01065-9","volume":"42","author":"Cheitlin","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2012.09.001_bib28","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","author":"Hunt","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2012.09.001_bib29","unstructured":"Herceptin prescribing information. Available at: http:\/\/www.herceptin.com\/pdf\/herceptin-prescribing.pdf. Accessed November 3,\u00a02012."}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177912000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177912000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T10:00:51Z","timestamp":1539856851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177912000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S2213177912000030"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2012.09.001","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}